A Real-World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment

被引:14
|
作者
Lombard, Louise [1 ]
Nutr, M. [1 ]
Ye, Wenyu [1 ]
Nichols, Russell [1 ]
Jackson, James [2 ]
Cotton, Sarah [2 ]
Joshi, Shivang [3 ,4 ]
机构
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Adelphi Real World, Adelphi Mill, Bollington, England
[3] DENT Neurol Inst, Amherst, NY USA
[4] Univ Buffalo, Sch Pharm, Buffalo, NY USA
来源
HEADACHE | 2020年 / 60卷 / 07期
关键词
migraine; responder; insufficient responder; real-world; acute treatment; UNITED-STATES; PREVALENCE; HEADACHE; PREVENTION; NONRESPONDERS; DISABILITY; TRIALS; ADULTS;
D O I
10.1111/head.13835
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective The objective of this study was to examine if patients with migraine who responded sufficiently to acute treatment were significantly different from those who did not in terms of patient characteristics, treatment patterns, and patient level of impairment, and to identify characteristics associated with insufficient response. Background Migraine is highly prevalent and impacts functional ability substantially. Current treatment approaches are not sufficiently meeting the needs of patients, and inadequate response to acute treatment is reported by at least 56% of patients with migraine in the United States. Methods Data were obtained from the 2014 Adelphi Migraine Disease-Specific Program, a cross-sectional survey. Using logistic regression, we assessed the association between patient factors and insufficient response. Responders were defined as patients with migraine who achieved pain freedom within 2 hours of acute treatment in >= 4 of 5 attacks, while insufficient responders achieved it in <= 3 of 5 attacks. Results Of 583 patients included, insufficient responders to acute treatment constituted 34.3% (200/583) of the study population. A statistically significantly larger proportion of insufficient responders vs responders had >= 4 migraine headache days/month (46.3% [88/190] vs 31% [114/368]), had ever been prescribed >= 3 unique preventive treatment regimens (11.7% [21/179] vs 6.3% [22/347]), and had chronic migraine, medication-overuse headaches, and comorbid depression (all P values <=.05). Patient level of impairment was statistically significantly greater among insufficient responders vs responders. Factors associated with insufficient response after adjusting for covariates included Migraine Disability Assessment total score (odds ratio [OR] = 1.04, 95% CI [1.02, 1.05]), time of administration of acute treatment (OR = 1.83, 95% CI [1.15, 2.92]), depression (OR = 1.98, 95% CI [1.21, 3.23]), sensitivity to light not listed as current most troublesome symptom (OR = 2.30, 95% CI [1.21, 4.37]), and change in the average headache days per month before being prescribed an acute treatment vs now (OR = 1.75, 95% CI [1.05, 2.90]). Conclusions Clinical characteristics, treatment patterns, and health-related quality of life measures are statistically significantly different between insufficient responders and responders to acute treatment in patients with migraine.
引用
收藏
页码:1325 / 1339
页数:15
相关论文
共 50 条
  • [41] Real-World Findings on the Characteristics and Treatment Exposures of Patients with Hidradenitis Suppurativa from US Claims Data
    Amit Garg
    Haley B. Naik
    Afsaneh Alavi
    Paul Hazen
    Jennifer L. Hsiao
    Vivian Y. Shi
    Jamie Weisman
    Tanja Tran
    Jan Rudnik
    Adam Jedrzejczyk
    Ingrid Pansar
    Alexa B. Kimball
    Dermatology and Therapy, 2023, 13 : 581 - 594
  • [42] Real-World Findings on the Characteristics and Treatment Exposures of Patients with Hidradenitis Suppurativa from US Claims Data
    Garg, Amit
    Naik, Haley B.
    Alavi, Afsaneh
    Hazen, Paul
    Hsiao, Jennifer L.
    Shi, Vivian Y.
    Weisman, Jamie
    Tran, Tanja
    Rudnik, Jan
    Jedrzejczyk, Adam
    Pansar, Ingrid
    Kimball, Alexa B.
    DERMATOLOGY AND THERAPY, 2023, 13 (02) : 581 - 594
  • [43] Real-World Open-Label Experience with Rimegepant for the Acute Treatment of Migraine Attacks: A Multicenter Pilot Study
    Dermitzakis, Emmanouil V.
    Rikos, Dimitrios
    Vikelis, Michail
    Xiromerisiou, Georgia
    Zisopoulou, Styliani
    Rallis, Dimitrios
    Soldatos, Panagiotis
    Vlachos, George S.
    Vasiliadis, Georgios G.
    Argyriou, Andreas A.
    BRAIN SCIENCES, 2024, 14 (12)
  • [44] Real-world treatment patterns of novel drugs in relapsed or refractory acute lymphoblastic leukemia patients in Japan
    Moribe, Toyoki
    Xu, Linghua
    Tajima, Kentaro
    Yonemoto, Naohiro
    FUTURE ONCOLOGY, 2023, 19 (19) : 1343 - 1356
  • [45] Insights from Real-World Analysis of Treatment Patterns in Patients with Newly Diagnosed Knee Osteoarthritis
    Dysart, Stan
    Utkina, Karina
    Stong, Laura
    Nelson, Winnie
    Sacks, Naomi
    Healey, Bridget
    Niazi, Faizan
    AMERICAN HEALTH AND DRUG BENEFITS, 2021, 14 (02) : 56 - 62
  • [46] Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
    Driessen, Maurice T.
    Cohen, Joshua M.
    Thompson, Stephen F.
    Patterson-Lomba, Oscar
    Seminerio, Michael J.
    Carr, Karen
    Totev, Todor, I
    Sun, Rochelle
    Yim, Erica
    Mu, Fan
    Ayyagari, Rajeev
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01)
  • [47] Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan
    Suzuki, Shiho
    Suzuki, Keisuke
    Shiina, Tomohiko
    Haruyama, Yasuo
    Hirata, Koichi
    FRONTIERS IN NEUROLOGY, 2023, 14
  • [48] A single-center retrospective study of onabotulinumtoxinA for treatment of 245 chronic migraine patients: survey results of a real-world experience
    Dikmen, Pinar Yalinay
    Kosak, Seda
    Aydinlar, Elif Ilgaz
    Kocaman, Ayse Sagduyu
    ACTA NEUROLOGICA BELGICA, 2018, 118 (03) : 475 - 484
  • [49] Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada
    Lee, Jason K.
    Amin, Suvina
    Erdmann, Michelle
    Kukaswadia, Atif
    Ivanovic, Jelena
    Fischer, Aren
    Gendron, Alain
    PATIENT PREFERENCE AND ADHERENCE, 2020, 14 : 725 - 735
  • [50] Effectiveness of long-term bimekizumab treatment and predictive factors for responders in moderate-to-severe psoriasis: A 52-week real-world study
    Hagino, Teppei
    Saeki, Hidehisa
    Fujimoto, Eita
    Kanda, Naoko
    JOURNAL OF DERMATOLOGY, 2025, 52 (02) : 317 - 328